Medical
About Us
Publication
Halloran S, Launoy G, Zappa M. European Commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition – Faecal Occult Blood Testing. Endoscopy 2012; 44:SE65–SE87. PubMed > |
National Institute for Health and Care Excellence. NICE guideline NG12. Suspected cancer: recognition and referral. Published 2015. NICE website > |
U.S. Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PubMed > |
U.S. Multi-Society Task Force. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2017; Volume 153, Issue 1, 307-323. PubMed > |
Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ Mar 2016, 188 (5) 340-348. PubMed > |
Lin JS, Piper M, Perdue LA, et al. Screening for Colorectal Cancer: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 135. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14 05203-EF-1. PubMed > |
National Institute for Health and Care Excellence. NICE guideline DG56. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Published 2023. NICE website > |
Monahan KJ, Davies MM, Abulafi M, et al. Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG)Gut 2022;71:1939-1962. PubMed > |
Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J. 2013;1(3):198-205. PubMed > |
Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697-706. PubMed > |
Zubero MB, Arana-Arri E, Pijoan JI, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol. 2014;4:175. PubMed > |
Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur J Cancer. 2012;48(16):2969-76. PubMed > |
Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int J Biol Markers. 2006;21(3):157-61. PubMed > |
Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014;147(6):1317-26. PubMed > |
van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009;101(8):1274-81. PubMed > |
van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62(3):409-15. PubMed > |
Sali L, Grazzini G, Carozzi F, et al. Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study). Trials. 2013 Mar 15;14:74. PubMed > |
Santare D, Kojalo I, Huttunen T, et al. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol. 2015;27(5):536–543. PubMed > |
Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121(18):3221-9. PubMed > |
Chiu H, Jen GH, Wang Y, et al. Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers. Gut 2021;70:2321-2329. PubMed > |
Pellat, A., Deyra, J., Coriat, R. et al. Results of the national organised colorectal cancer screening program with FIT in Paris. Sci Rep 8, 4162 (2018). PubMed > |
Baldacchini F, Bucchi L, Giuliani O. et al..Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2373-2382. PubMed > |
Castells A, Quintero E, Bujanda L, et al. ; COLONPREV study investigators. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025 Apr 12;405(10486):1231-1239. PubMed > |
Vilkin A, Rozen P, Levi Z, et al. Performance Characteristics and Evaluation of an Automated-Developed and Quantitative, Immunochemical, Fecal Occult Blood Screening Test. Am J Gastroenterol. 2005;100(11):2519-25. PubMed > |
Miki I, Maki H, Ikuhiro M, Yoh H. Evaluation of the analytical performance of the new compact, tabletop, discrete-type automated clinical chemistry analyzer "OC-SENSOR Ceres" for fecal occult blood testing. The Journal of Clinical Laboratory Instruments and Reagents. 2021; 44(3):258-264. “We evaluated the analytical performance of OC-SENSOR Ceres in fecal occult blood quantification and obtained overall good results. “ |
Piggott C, Carroll MRR, et al. Analytical evaluation of four faecal immunochemistry tests for haemoglobin. Clin Chem Lab Med. 2020 Jul 21;59(1):173-178. PubMed > |
Chen LS, Yen AM, Chiu SY, et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol. 2011;12(6):551-8. PubMed > |
Peng SM, Chiu HM, Jen HH, et al. Quantile-based fecal hemoglobin concentration for assessing colorectal neoplasms with 1,263,717 Taiwanese screenees. BMC Med Inform Decis Mak. 2019;19(1):94. PubMed > |
Grobbee EJ, Schreuders EH, Hansen BE, et al. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. Gastroenterology. 2017;153(5):1251-1259.e2. PubMed > |
Deding U, Kaalby L, et al. Faecal haemoglobin concentration predicts all-cause mortality. Eur J Cancer. 2023 May;184:21-29. PubMed > |
van den Berg DMN, van den Puttelaar R, et al. Fecal Hemoglobin Levels in Prior Negative Screening and Detection of Colorectal Neoplasia: A Dose-Response Meta-Analysis. Gastroenterology. 2025 Mar;168(3):587-597. PubMed > |
Goede SL, van Roon AH, Reijerink JC, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut. 2013;62(5):727-34. PubMed > |
Oort FA, van Turenhout ST, Coupé VM, et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer. 2011;11:434. PubMed > |
Young GP, Woodman RJ, Symonds E. Detection of advanced colorectal neoplasia and relative colonoscopy workloads using quantitative faecal immunochemical tests: an observational study exploring the effects of simultaneous adjustment of both sample number and test positivity threshold. BMJ Open Gastroenterol. 2020 Sep;7(1):e000517. PubMed > |
Toyoshima O, Yamaji Y, et al. Priority stratification for colonoscopy based on two-sample faecal immunochemical test screening: results from a cross-sectional study at an endoscopy clinic in Japan. BMJ Open. 2021 May 19;11(5):e046055 PubMed > |
Gerrard AD, Maeda Y, Miller J, Gunn F, Theodoratou E, Noble C, Porteous L, Glancy S, MacLean P, Pattenden R, Dunlop MG, Din FVN; Edinburgh Colorectal Group. Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer. Br J Surg. 2023 Mar. PubMed > |
Portillo I, Arana-Arri E, Idigoras I, et al. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World J Gastroenterol. 2017;23(15):2731-2742. PubMed > |
Digby J, Fraser CG, Carey FA, et al. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. J Med Screen. 2016;23(3):130-4. PubMed > |
Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011;103(23):1741-51. PubMed > |
van Rossum LG, van Rijn AF, Laheij RJ, et al. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology, 2008;135(1):82-90. PubMed > |
Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26(3):131-47. PubMed > |
van Rossum LG, van Rijn AF, Verbeek AL, et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer. 2011;128(8):1908-17. PubMed > |
Bretagne JF, Carlo A, et al. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme. Br J Cancer. 2021 Nov;125(11):1494-1502. PubMed > |